pd-1
Celgene plays catch up with $1.4 billion immunotherapy deal
July 7, 2017Medical Communications, Sales and Marketing BeiGene, Celgene, immunotherapy, pd-1
Those commentating on Celgene’s latest deal seem to be equally divided between two camps: it is too much money, too …
FDA shutters MSD’s Keytruda combination trials in myeloma
July 6, 2017Medical Communications, Research and Development MSD, immunotherapy, keytruda, pd-1
Following on from the news last month that enrolment for Keytruda being used alongside Celgene’s Imnovid and Revlimid would have …
MSD’s Keytruda impresses in lung cancer chemotherapy trial
December 21, 2015Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab
MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …
Sanofi and Regeneron in immuno-oncology push
July 28, 2015Manufacturing and Production, Research and Development Cancer, PD-1 inhibitors, Regeneron, Sanofi, collaboration, immuno-oncology, pd-1
Pharma giants Sanofi and Regeneron are extending the partnership that brought new heart drug Praluent to the market, with a …
‘Postcode lottery’ still cause of many lung cancer deaths
December 3, 2014Research and Development, Sales and Marketing DoH, Roche, astranzeneca, lung cancer, nlca, oncology, pd-1
Patients are still pointlessly dying of lung cancer due to a ‘postcode lottery’ of services according to new results from …
Merck surprise winner in PD-1 race
September 5, 2014Medical Communications, Research and Development, Sales and Marketing Cancer, Merck, melanoma, pd-1
Merck has become the first company to bring a new class of cancer drug to the US market after the …
AZ shares climb on positive cancer drug news
September 1, 2014Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Pfizer, immunoc-oncology, pd-1
AstraZeneca has moved a key new oncology drug into mid-stage trials as it looks to shore up its cancer research …
Merck and Advaxis team up on immuno-oncology
August 26, 2014Manufacturing and Production, Medical Communications, Research and Development ASCO, Merck, immunology, pd-1, pembrolizumab
Advaxis and Merck have signed a research deal to investigational Merck’s PD-1 inhibitor pembrolizumab in combination with Advaxis’ listeria-based cancer …
BMS to make Opdivo submission
July 11, 2014Sales and Marketing BMS, Cancer, EMA, FDA, ono, opdivo, pd-1
Bristol-Myers Squibb is to submit cancer treatment Opdivo to the US authorities after the drug received its first approval in …
